Molecular approaches to the discovery of new treatments for obesity

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 204-209

  Strader, Catherine D ^a   MacIntyre, D Euan ^a   Candelore, Mari R ^a   Parker, Eric M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LEPTIN; PROTEIN;

APPETITE; BODY WEIGHT; CHEMICAL STRUCTURE; ENERGY METABOLISM; HUMAN; METABOLISM; OBESITY; REVIEW;

ANTI-OBESITY AGENTS; APPETITE; BODY WEIGHT; ENERGY METABOLISM; HUMANS; LEPTIN; MODELS, MOLECULAR; OBESITY; PROTEINS;

EID: 0031197027     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80011-7     Document Type: Article

References (50)

1. Leibel RL, Rosenbaum M, Hirsch J: Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995, 332:621-628.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-431.
3. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn PR: Recombinant mouse ob protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995, 269:546-548.
4. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Freidman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
5. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543.
6. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE et al.: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
7. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CT, Hess JF: Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996, 13:18-19.
8. Hwa JJ, Fawzi AB, Graziano MP, Ghibaudi L, Williams P, Van Heek M, Davis H, Rudinski M, Sybertz E, Strader CD: Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol 1997, 8:1204-1209.
9. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffman J, Hsiung HM, Kriauciunas A et al.: The role of neuropeptide Y in the antiobesity action of the obese gene product Nature 1995, 377:530-532.
10. Hwa JJ, Ghibaudi L, Williams P, Compton D, Fawzi AB, Strader CD: Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. Horm Metab Res 1996, 28:659-663.
11. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang P, Sinha MK, Considine RV: Decreased cerebrospinal fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996, 348:159-161.
12. Schwartz MW, Peskind E, Raskind M, Boyko E, Porte D: Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996; 2:589-593.
13. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM: Leptin enters the brain by a saturable system independent of insulin. Peptides 1996, 17:305-311.
14. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD: Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997, 99:385-390.
15. 1 receptor mediating this peptide's effect Peptides 1992, 13:581-587.
16. Billington CJ, Briggs JE, Grace M, Levine AS: Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991, 260:R321-R327.
17. Akibayashi A, Wahlestedt C, Alexander JT, Leibowitz SF: Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Mol Brain Res 1994, 21:55-61.
18. Dube MG, Xu B, Crowley WR, Kalra PS, Kalra SP: Evidence that neuropeptide Y is a physiological signal for normal food intake. Brain Res 1994, 646:341-344.
19. Wilding JPH, Gilbey SG, Bailey CJ, Batt RAL, Williams G, Ghatei MA, Bloom SR: Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 1993, 132:1939-1944.
20. Erickson JC, Hollopeter G, Palmiter RD: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Nature 1996, 274:1704-1707. These authors mated transgenic mice lacking NPY with ob/ob mice. The resulting NPY- and leptin-deficient mice were markedly less obese than the ob/ob parental strain. The offspring also had lower serum glucose and insulin levels and were more fertile than the ob/ob parental strain.
21. 1 type. J Biol Chem 1992, 267:10935-10938.
22. Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, Kienzle B, Seethala R: Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995, 270:22661-22664.
23. 1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life Sci 1992, 50:PL7-PL12.
24. Bard JA, Walker MW, Branchek TA, Weinshank RL: Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 1995, 270:26762-26765.
25. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL et al.: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382:168-171. This paper described the cloning of the NPY Y5 receptor which has pharmacological properties that closely match the pharmacological properties of the receptor that mediates the effects of NPY on feeding behavior, and appears to be the preferred target for anti-obesity drugs.
26. Weinberg DH, Sirinathsinghji DJS, Tan CP, Shiao L-L, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA et al.: Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 1996, 271:16435-16438.
27. 1, Y2 and Y3 receptors. Eur J Pharmacol 1995, 278:R3-R5.
28. O'Shea D, Morgan DGA, Meeran K, Edwards CMB, Turton MD, Choi SJ, Heath MM, Gunn I, Taylor GM, Howard JK et al.: Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 1997, 138:196-202.
29. 1 receptor antagonists. Drug Discov Today 1997, 2:19-24.
30. 1 receptor antagonist. FEBS Lett 1995, 362:192-196.
31. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS: Role of leptin in fat regulation. Nature 1996, 380:677.
32. Nicholls DG, Locke RM: Thermogenic mechanisms in brown fat Physiol Rev 1984, 64:1-64.
33. Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms- Hagen J, Boyer BB, Kozak LP, Flier JS: Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993, 366:740-742.
34. Hamann A, Benecke H, Le Marchand-Brustel Y, Susulic VS, Lowell BB, Flier JS: Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 1995, 44:1266-1273.
35. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi- Meyrueis C, Bouillard F, Seldin MF, Surwit RS, Ricquier D, Warden CH: Uncoupling protein 2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997, 15:269-272. This paper describes a novel uncoupling protein (UCP2) with homology to UCP1 but a much more widespread tissue distribution, suggesting the potential for regulation of energy dissipation in tissues other than the relatively nonabundant BAT.
36. Tan S, Curtis-Prior PB: Characterization of the beta adrenoceptor of the adipose cell of the rat. Int J Obesity 1983, 7:409-414.
37. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennit MV, Thody VE, Wilson, C, Wilson S: Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309:161-165.
38. Champigny O, Ricquier D, Blondel O, Mayers RM, Briscoe MG, Holloway BR: β3-Adrenergic receptor stimulation restores message and expression of brown fat mitochondrial uncoupling protein in adult dogs. Proc Natl Acad Sci USA 1991, 88:10774-10777.
39. Himms-Hagen J: Brown adipose tissue metabolism. In Obesity, Edited by Bjorntorp P, Brodoff BN. Philadelphia; Lippincott: 1992:15-34.
40. Bloom JD, Claus TH: CL 316,243. Drugs Future 1994, 19:23-26.
41. Smith SA, Sennitt MV, Cawthorne MA: BRL 35135: an orally active antihyperglycaemic agent with weight reducing effects. In New Antidiabetic Drugs. Edited by Bailey CJ, Flatt PR. London: Smith-Gordon; 1990:177-189.
42. Arbeeny CM, Meyers DS, Hillyer DE, Bergquist KE: Metabolic alteration associated with the antidiabetic effect of β3-adrenergic receptor agonist in obese mice. Am J Physiol 1995, 268:E678-E684.
43. Goldberg GR, Prentice AM, Murgatroyd PR, Haines W, Tuersley MD: Effects on metabolic rate and fuel selection of a selective β-3 agonist (ICI D7114) in healthy men. Int J Obesity 1995, 19:625-631.
44. Lipworth BJ: Clinical pharmacology of β3-adrenoceptors. Br J Clin Pharmacol 1996, 42:291-300.
45. Connacher AA, Jung RT, Mitchell PEG: Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta-adrenoceptor agonist. BMJ 1988, 296:1217-1220.
46. Connacher AA, Lakie M, Powers N, Elton RA, Walsh EG, Jung RT: Tremor and the anti-obesity drug BRL 26830A. Br J Clin Pharmacol 1990, 30:613-615.
47. Emorine LJ, Marullo S, Briend-Sutren M-M, Patey G, Tate K, Dalavier-Klutchko C, Strosberg AD: Molecular characterization of the human beta3-adrenergic receptor. Science 1989, 245:1118-1121.
48. Liggett SB: Functional properties of the rat and human β3 adrenergic receptors: differential agonist activation of recombinant receptors in CHO cells. Mol Pharm 1992, 42:634-637.
49. Giacobino JP: β3-Adrenoceptor: an update. Eur J Endocrinol 1995, 132:377-385.
50. Strosberg AD, Pietri-Rouxel F: Function and regulation of the β3-adrenoceptor. Trends Pharmacol Sci 1996, 17:373-381.